Joo Kwon retrospectively reviewed the medical records of DEB patients with refractory pruritus who were treated with either baricitinib, a JAK1/2 inhibitor, or upadacitinib, a selective JAK1 inhibitor. The gene discussed is JAK1; the disease is Dystrophic epidermolysis bullosa.